Spruce Street Capital LP

In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 13, 2026), Spruce Street Capital LP reported 30 stock positions worth $509.7 million. Its top holding was Kiniksa Pharmaceuticals Inte (KNSA) at 11.5% of the portfolio, followed by Relay Therapeutics (RLAY, 11.0%) and LB Pharmaceuticals (LBRX, 8.8%). Compared with Q1 2026, it opened 5 new positions, sold out of 3, added to 8 and reduced 1. The biggest buy was Alkermes (ALKS, shares +71%) and the biggest sale an exit from Centessa Pharmaceuticals (CNTA).

Most Recent 13F
Q2 2026
Location
NEW YORK, NY
CIK
0002050194
Portfolio Value
$509.7M (Q2 2026)
SEC Filing
0002050194-26-000005 ↗ filed Aug 13, 2026

Holdings Value

0$200.0M$400.0M$600.0M Q4 2025: $302.7M Q4 2025 Q1 2026: $415.9M Q1 2026 Q2 2026: $509.7M $509.7M Q2 2026

Holdings 30 stocks · $509.7M
KNSA Kiniksa Pharmaceuticals Inte 11.52% 918,070 $58.7M Add +20.6%
RLAY Relay Therapeutics Inc. 10.95% 2,984,125 $55.8M No change
LBRX LB Pharmaceuticals Inc. 8.76% 1,376,159 $44.7M No change
RLMD Relmada Therapeutics Inc. 8.68% 6,391,328 $44.2M Add +2.1%
ANRO Alto Neuroscience Inc. 7.01% 1,353,047 $35.7M Add +2.1%
DNTH Dianthus Therapeutics Inc. 6.79% 354,816 $34.6M Reduce -4.9%
ALKS Alkermes PLC 5.59% 543,876 $28.5M Add +71.0%
SVRA Savara Inc. 4.17% 3,452,576 $21.3M Add +2.0%
PCVX Vaxcyte Inc. 3.49% 306,047 $17.8M Add +24.6%
ELVN Enliven Therapeutics Inc. 3.28% 329,006 $16.7M No change
ENTA Enanta Pharmaceuticals Inc. 3.11% 1,088,731 $15.9M Add +16.7%
CATX Perspective Therapeutics Inc. 2.47% 3,693,931 $12.6M Add +40.6%
IFRX Inflarx NV 2.35% 5,352,198 $12.0M New
SRZN Surrozen Inc. 2.20% 432,040 $11.2M No change
ALMS Alumis Inc. 2.17% 392,574 $11.0M No change
IPSC Century Therapeutics Inc. 1.95% 4,059,054 $9.9M No change
NERV Minerva Neurosciences Inc. 1.80% 1,655,500 $9.2M No change
SABS Sab Biotherapeutics Inc. 1.68% 2,198,502 $8.6M No change
ANTX AN2 Therapeutics Inc. 1.58% 1,661,073 $8.0M No change
ERAS Erasca Inc. 1.52% 422,543 $7.7M No change
IKT Inhibikase Therapeutics Inc. 1.43% 3,581,603 $7.3M No change
RACC Research Alliance Corp. Class A 1.05% 500,000 $5.3M New
HLXC Helix Acquisition Corp. Class A 1.04% 500,000 $5.3M No change
ZLAB Zai Lab Ltd.-ADR 1.04% 279,110 $5.3M New
ACHV Achieve Life Sciences Inc. 0.94% 736,637 $4.8M New
LXEO Lexeo Therapeutics Inc. 0.85% 928,593 $4.3M No change
ALEC Alector Inc. 0.83% 2,101,068 $4.2M No change
LONA Leonabio Inc. 0.71% 393,701 $3.6M No change
CRVS Corvus Pharmaceuticals Inc. 0.68% 231,585 $3.5M No change
JATT Jatt II Acquisition Corp. 0.36% 160,000 $1.8M New

Portfolio Sells Q1 2026 → Q2 2026
CNTA Centessa Pharmaceuticals Ltd. Sold out 0.00% −4.68
KALV Kalvista Pharmaceuticals Inc. Sold out 0.00% −4.34
MAZE Maze Therapeutics Inc. Sold out 0.00% −1.44
DNTH Dianthus Therapeutics Inc. Reduce -4.9% 6.79% −0.75

Portfolio Buys Q1 2026 → Q2 2026
ALKS Alkermes PLC Add +71.0% 5.59% +2.89
KNSA Kiniksa Pharmaceuticals Inte Add +20.6% 11.52% +2.71
IFRX Inflarx NV New 2.35% +2.35
RACC Research Alliance Corp. Class A New 1.05% +1.05
ZLAB Zai Lab Ltd.-ADR New 1.04% +1.04
ACHV Achieve Life Sciences Inc. New 0.94% +0.94
JATT Jatt II Acquisition Corp. New 0.36% +0.36
ENTA Enanta Pharmaceuticals Inc. Add +16.7% 3.11% +0.28
PCVX Vaxcyte Inc. Add +24.6% 3.49% +0.06
ANRO Alto Neuroscience Inc. Add +2.1% 7.01% +0.01
CATX Perspective Therapeutics Inc. Add +40.6% 2.47% −0.16
SVRA Savara Inc. Add +2.0% 4.17% −0.27
RLMD Relmada Therapeutics Inc. Add +2.1% 8.68% −1.66

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 30$509.7MKNSA, RLAY, LBRX, RLMD, ANRO
Q1 2026 28$415.9MRLMD, KNSA, LBRX, DNTH, RLAY
Q4 2025 27$302.7MCDTX, RLAY, LBRX, RLMD, PCVX